Karuna Therapeutics, Inc (KRTX)

Etorro trading 970x250
Karuna Therapeutics, Inc (KRTX) Logo

About Karuna Therapeutics, Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Address: 33 Arch Street, Boston, MA, United States, 02110

Karuna Therapeutics, Inc News and around…

Latest news about Karuna Therapeutics, Inc (KRTX) common stock and company :

We Think Karuna Therapeutics (NASDAQ:KRTX) Can Afford To Drive Business Growth
19 May, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
18 May, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET. The one-hour webcast event will highlight progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for the treatment of psychosis in Alzheimer’s disease.

Noteworthy Thursday Option Activity: WING, KRTX, NOC
05 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Wingstop Inc (WING), where a total volume of 3,752 contracts has been traded thus far today, a contract volume which is representative of approximately 375,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 55.2% of WING's average daily trading volume over the past month, of 679,455 shares..

Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss
05 May, 2022 Yahoo! Finance

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

Karuna Therapeutics: Q1 Earnings Insights
05 May, 2022 FinancialContent

Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what ...

Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
05 May, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update.

Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
03 May, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 8:00 a.m. ET.

What 4 Analyst Ratings Have To Say About Karuna Therapeutics
27 Apr, 2022 FinancialContent

Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Investors in Karuna Therapeutics (NASDAQ:KRTX) have made a return of 22% over the past year
17 Apr, 2022 Yahoo! Finance

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

Karuna Therapeutics Larger Than S&P 500 Component Warner Bros Discovery
06 Apr, 2022 FinancialContent

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Karuna Therapeutics Inc (KRTX) was identified as having a larger market cap than the smaller end of the S&P 500, for example Warner Bros Discovery Inc (DISCA), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
31 Mar, 2022 FinancialContent

Upgrades Raymond James upgraded the previous rating for Starwood Property Trust Inc (NYSE:STWD) from Outperform to Strong Buy. For the ...

KRTX Makes Bullish Cross Above Critical Moving Average
22 Mar, 2022 FinancialContent

In trading on Tuesday, shares of Karuna Therapeutics Inc (KRTX) crossed above their 200 day moving average of $119.65, changing hands as high as $119.80 per share. Karuna Therapeutics Inc shares are currently trading up about 2.7% on the day..

Karuna Therapeutics to Present at Upcoming Investor Conferences
10 Mar, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming virtual investor conferences:

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
24 Feb, 2022 FinancialContent

According to an SEC filing,Karuna Therapeutics Inc(NASDAQ: KRTX) is withdrawing its prior guidance for the timing of ...

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
24 Feb, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update.

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster
22 Feb, 2022 Yahoo! Finance

Analysts say company is taking novel approach to treating mental illnesses, Alzheimer's

Notable Friday Option Activity: KRTX, DLTR, BLMN
18 Feb, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Karuna Therapeutics Inc (KRTX), where a total volume of 972 contracts has been traded thus far today, a contract volume which is representative of approximately 97,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 47.9% of KRTX's average daily trading volume over the past month, of 203,025 shares..

One Karuna Therapeutics, Inc. (NASDAQ:KRTX) insider upped their stake by 2.2% in the previous year
16 Feb, 2022 Yahoo! Finance

Viewing insider transactions for Karuna Therapeutics, Inc.'s ( NASDAQ:KRTX ) over the last year, we see that insiders...

Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ...
02 Feb, 2022 Yahoo! Finance

Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.

Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
01 Feb, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:00 a.m. ET.

3 Can't-Miss Biotech Events Coming Up in 2022
07 Jan, 2022 FinancialContent

This could be a very exciting year for these drugmakers.

Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan, 2022 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. ET.

Cramer Talks to Karuna's CEO About New Schizophrenia Treatments
20 Dec, 2021 Yahoo! Finance

On a recent episode of "Mad Money," Jim Cramer heard from a company that is developing novel ways to treat some of society's most vexing brain disorders. Dr. Steve Paul, chairman, president and CEO of Karuna Therapeutics , told Cramer the clinical-stage biotech is working to develop best-in-class treatments for patients suffering from schizophrenia, Alzheimers and other mental health disorders. Paul explained that many of the treatments used to treat schizophrenia today are similar to ones developed in the mid-20th century.

Add Up The Pieces: FPX Could Be Worth $153
03 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust US Equity Opportunities ETF (FPX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $153.12 per unit.

Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak
02 Dec, 2021 Yahoo! Finance

The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.

This Metaverse Stock Will Be Featured On 'Mad Money' Wednesday Night
01 Dec, 2021 FinancialContent

Unity Software Inc (NYSE: U) CEO John Riccitiellowill be featured Wednesday on "Mad Money" with Jim Cramer. Unity ...

Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
29 Nov, 2021 FinancialContent

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021.

Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
13 Nov, 2021 FinancialContent

Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.

Why Karuna Therapeutics Stock Tumbled This Week
12 Nov, 2021 FinancialContent

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

76 Biggest Movers From Yesterday
11 Nov, 2021 FinancialContent

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per ...

Karuna Therapeutics, Inc (KRTX) is a NASDAQ Common Stock listed in , ,

970x250